Enanta Pharmaceuticals (ENTA) Net Cash Flow (2012 - 2026)

Enanta Pharmaceuticals (ENTA) has 15 years of Net Cash Flow data on file, last reported at -$2.5 million in Q1 2026.

• Quarterly Net Cash Flow rose 89.86% year-over-year to -$2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$25.3 million (down 542.24% YoY) and the FY2025 annual result came in at -$5.5 million, up 88.49% from the prior year.
• Net Cash Flow fell to -$2.5 million in Q1 2026, from $5.1 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $47.1 million in Q4 2024 to a low of -$58.1 million in Q1 2022.
• A 5-year average of -$3.6 million and a median of -$2.5 million in 2026 frame the typical range for Net Cash Flow.
• The widest YoY moves for Net Cash Flow: up 337.52% in 2023, down 2466.63% in 2023.
• Tracing ENTA's Net Cash Flow over 5 years: stood at -$1.8 million in 2022, then plunged by 2466.63% to -$45.5 million in 2023, then soared by 203.65% to $47.1 million in 2024, then slumped by 89.09% to $5.1 million in 2025, then sank by 148.82% to -$2.5 million in 2026.
• The last three Net Cash Flow figures came in at -$2.5 million (Q1 2026), $5.1 million (Q4 2025), and -$12.5 million (Q3 2025), per Business Quant data.